SomaLogic Proteomics Research Grant for Australia

Apply today! Each winner will receive high-plex proteomic data analysis of 40 samples to accelerate their research.


SomaLogic is pleased to announce the SomaLogic Proteomics Research Grant for Australia. Each successful applicant will receive high-plex proteomic data for 40 samples of human serum or plasma. Analysis will be performed using the SomaScan® Assay 7,000 protein menu. Each winning grant is valued at USD $30,000.

Program details

SomaLogic invites researchers in Australia to submit a brief outline of their inventive plans to use the SomaScan Assay in their research. The goal of this program is to assist researchers in Australia to generate pilot data, which can be used to support their future grant applications, and to promote use of the SomaScan Assay as an essential tool for generating high-quality proteomic data. Applicants’ proposals will be reviewed within 4 weeks of the submission deadline (30 November 2023).

Applicants should write a short proposal of 500 words or less, outlining a pilot research project which uses the SomaScan Assay.

A committee of SomaLogic staff will review and select the winning applicant based on the following criteria:

  • The overall application completeness
  • Did the applicant have an original proposal with clear goals and outcomes
  • Provide a clear approach and design which matches the goals and outcomes
  • How the protein data and analysis are intended to be used
  • What are the next steps the researcher intends to take with this additional knowledge
  • How does SomaScan data increase insight into health and disease for their given focus area
  • How does application show complementary use of SomaScan Assay with other technologies to fill in gaps where other technologies cannot support


Two (2) winners will be selected and awarded forty (40) samples to be processed on the SomaScan Assay, together with upstream and downstream support from SomaLogic (including discussions with technical support to validate sample type and discuss limitations and with the project management team to discuss sample prep/shipping and downstream bioinformatic support), excluding shipment costs to the U.S. The samples for this program need to be banked, frozen, and ready for use.

If applicants have any questions about sample submission requirements, they should email SomaLogic at [email protected].

Application timelines

Grant will be announced by SomaLogic and advertised via SomaLogic’s database to eligible customers in Australia.


1 October 2023


1 October 2023
Submission close 30 November 2023 – Submissions for this grant program are closed. Late submissions not accepted

Winner announced

15 January 2024

Samples submitted for processing

28 February 2024

Data from SomaScan Assay delivered

End of March 2024

Eligibility criteria

  1. The grant program terms and conditions apply and are available here.
  2. The grant is only open to researchers who are based in Australia and based at an institution or group where they perform the research.
  3. Research teams who already use the SomaScan Assay are not eligible to apply.
  4. All submissions must be in English and comply with the criteria outlined here in this guide.
  5. The samples processed on the SomaScan Assay need to be available and meet certain criteria (Handling and Processing Guide, available from your SomaLogic Sales Manager here).
  6. Pilot studies which are creative, bring new insight to health and disease, and have potential to lead to longer term studies are highly considered.
  7. For questions about eligibility or the study you have proposed, please email SomaLogic at [email protected]
  8. Only one application per person is allowed.

Research grant conditions

  1. The two (2) successful applicants will receive SomaScan data for each of their 40 samples, including discussions with technical support to validate sample type and discuss limitations and with the project management team to discuss sample prep/shipping and downstream bioinformatic support. Applicants will own the SomaScan Assay data generated under this grant program.
  2. Samples will be run on the SomaScan Assay by SomaLogic at its CLIA-certified facility in Boulder, Colorado, USA.
  3. Application submission deadline is 30 November 2023. Any submissions made after this date will not be accepted.
  4. Successful applicants consent to their name and organization being used for promotional purposes under this grant program.
  5. The winner will be announced on 15 January 2024, by email, social media (Facebook, Twitter, LinkedIn) and be encouraged to present their research in SomaLogic marketing activities.
  6. For questions about your eligibility or the study you have proposed, please email SomaLogic at [email protected]
  7. The grant is for research purposes only and not to be used for commercial or clinical purposes.
  8. The applications will be reviewed and awarded by a SomaLogic committee, and a winner decided by same.
  9. SomaLogic’s decision is final on study feasibility.
  10. All applicants agree to be contacted by SomaLogic for marketing purposes.
  11. Special grant terms and conditions apply.

Sample submission

  • The grant winners will provide 40 samples to be run on the SomaScan Assay with the output product being data showing signals for 7000 protein targets.
  • Samples must be human plasma or serum. Other mammalian sample types may be considered after consultation.
  • Samples submitted must be 130 µl volume and prepared according to the SomaLogic Handling and Processing Guide (available here). Recording, delivery and labelling will be discussed with the winners.
  • Sample submissions, including any associated documentation, cannot include any personal or health information on human subjects. Awardees agree to comply with all applicable laws and regulations with their grant submission and, if awarded, their sample submissions.
  • Shipment of samples must be at awardee expense via suitable cold chain courier with dry ice top up with tracking, preferably.

The submission window for this grant program has closed